Literature DB >> 29916037

Non-Alzheimer's contributions to dementia and cognitive resilience in The 90+ Study.

John L Robinson1, Maria M Corrada2, Gabor G Kovacs1,3, Myrna Dominique1, Carrie Caswell4, Sharon X Xie4, Virginia M-Y Lee1, Claudia H Kawas5, John Q Trojanowski6.   

Abstract

The diagnosis of Alzheimer's disease (AD) in the oldest-old is complicated by the increasing prevalence of age-related neurofibrillary tangles, plaques and non-AD pathologies such as cerebrovascular disease (CVD), hippocampal sclerosis (HS), aging-related tau astrogliopathy (ARTAG), as well as TDP-43 and Lewy pathology. The contribution of these non-AD pathologies to dementia and cognitive resilience is unclear. We assessed the level of AD neuropathologic change (ADNPC) and non-AD pathology in 185 participants enrolled in The 90+ Study with available cognitive assessments and brain tissue. Logistic regression models-adjusting for age, sex and education-determined the association between each pathology and dementia or between subgroups. 53% had dementia, primarily AD or mixed AD; 23% had cognitive impairment without dementia (CIND); 23% were not impaired. Both AD and non-AD pathology was prevalent. 100% had tangles, 81% had plaques, and both tangles and plaques associated with dementia. ARTAG distributed across limbic (70%), brainstem (39%) and cortical regions (24%). 49% had possible CVD and 26% had definite CVD, while HS was noted in 15%. Cortical ARTAG, CVD and HS were each associated with dementia, but limbic and brainstem ARTAGs were not. TDP-43 and Lewy pathologies were found in 36 and 17% and both associated with dementia. No pathology distinguished CIND and the not impaired. By NIA-AA criteria and dementia status, the cohort was subdivided into four groups: those with minimal ADNPC included the not dementia (ND) and Not AD dementia groups; and those with significant ADNPC included the Resilient without dementia and AD dementia groups. Compared to the ND group, the Not AD dementia group had more HS, cortical ARTAG, TDP-43, and Lewy pathology. Compared to the AD dementia group, the Resilient group had less CVD, no HS and less cortical ARTAG, TDP-43 and Lewy pathology. Our findings imply that reductions in non-AD pathologies including CVD contribute to cognitive resilience in the oldest-old.

Entities:  

Mesh:

Year:  2018        PMID: 29916037      PMCID: PMC6534149          DOI: 10.1007/s00401-018-1872-5

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  36 in total

1.  Language and spatial dysfunction in Alzheimer disease with white matter thorn-shaped astrocytes.

Authors:  Elisa de Paula França Resende; Amber L Nolan; Cathrine Petersen; Alexander J Ehrenberg; Salvatore Spina; Isabel E Allen; Howard J Rosen; Joel Kramer; Bruce L Miller; William W Seeley; Maria Luiza Gorno-Tempini; Zachary Miller; Lea T Grinberg
Journal:  Neurology       Date:  2020-01-30       Impact factor: 9.910

2.  TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease.

Authors:  Marina Buciuc; Jennifer L Whitwell; Bradley F Boeve; Tanis J Ferman; Jonathan Graff-Radford; Rodolfo Savica; Kejal Kantarci; Julie A Fields; David S Knopman; Ronald C Petersen; Joseph E Parisi; Melissa E Murray; Dennis W Dickson; Keith A Josephs
Journal:  J Neurol       Date:  2020-01-31       Impact factor: 4.849

Review 3.  Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice.

Authors:  Leslie M Shaw; Magdalena Korecka; Michal Figurski; Jon Toledo; David Irwin; Ju Hee Kang; John Q Trojanowski
Journal:  J Appl Lab Med       Date:  2020-01-01

Review 4.  Neuroimmune interactions in Alzheimer's disease-New frontier with old challenges?

Authors:  Stefan Prokop; Virginia M Y Lee; John Q Trojanowski
Journal:  Prog Mol Biol Transl Sci       Date:  2019-10-24       Impact factor: 3.622

5.  Association between transactive response DNA-binding protein of 43 kDa type and cognitive resilience to Alzheimer's disease: a case-control study.

Authors:  Marina Buciuc; Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Melissa E Murray; Bradley F Boeve; David S Knopman; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson; Keith A Josephs
Journal:  Neurobiol Aging       Date:  2020-04-15       Impact factor: 4.673

6.  Phosphorylated and aggregated TDP-43 with seeding properties are induced upon mutant Huntingtin (mHtt) polyglutamine expression in human cellular models.

Authors:  Laurent Coudert; Takashi Nonaka; Emilien Bernard; Masato Hasegawa; Laurent Schaeffer; Pascal Leblanc
Journal:  Cell Mol Life Sci       Date:  2019-03-12       Impact factor: 9.261

7.  Neuropathological lesions in the very old: results from a large Brazilian autopsy study.

Authors:  Claudia K Suemoto; Renata E P Leite; Renata E L Ferretti-Rebustini; Roberta D Rodriguez; Ricardo Nitrini; Carlos A Pasqualucci; Wilson Jacob-Filho; Lea T Grinberg
Journal:  Brain Pathol       Date:  2019-04-10       Impact factor: 6.508

8.  Amount and delay insensitivity during intertemporal choice in three neurodegenerative diseases reflects dorsomedial prefrontal atrophy.

Authors:  Alexander J Beagle; Ali Zahir; Mia Borzello; Andrew S Kayser; Ming Hsu; Bruce L Miller; Joel H Kramer; Winston Chiong
Journal:  Cortex       Date:  2019-10-31       Impact factor: 4.027

9.  Astrocytic Tau Deposition Is Frequent in Typical and Atypical Alzheimer Disease Presentations.

Authors:  Amber Nolan; Elisa De Paula Franca Resende; Cathrine Petersen; Kyra Neylan; Salvatore Spina; Eric Huang; William Seeley; Zachary Miller; Lea T Grinberg
Journal:  J Neuropathol Exp Neurol       Date:  2019-12-01       Impact factor: 3.685

10.  Limbic Predominant Age-Related TDP-43 Encephalopathy (LATE): Clinical and Neuropathological Associations.

Authors:  Lilah M Besser; Merilee A Teylan; Peter T Nelson
Journal:  J Neuropathol Exp Neurol       Date:  2020-03-01       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.